Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice

EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States

EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 5.Decision-Making Process Surrounding Biosimilar Implementation

EP: 6.Biosimilar Administration Considerations Impacting Patient Experience

EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

EP: 8.Switching Patients from Reference Product to Biosimilar

EP: 9.Defining Interchangeability and Switching in Biologics

EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape

EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval

EP: 12.Harnessing Indication-Specific Data on Biosimilars

EP: 13.Cost Savings Related to Biosimilars

EP: 14.Payers and PBMs Impacted by Biosimilar Integration

Now Viewing

EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars

EP: 17.Key Points of Emphasis Regarding Biosimilar Integration

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Haumschild asks Gottlieb how payers can support biosimilar utilization to lower health care costs beyond just acquisition costs. Gottlieb says payers and pharmacy benefit managers should focus less on segment profit and more on reducing patient costs.

Haumschild notes that integrated specialty pharmacies improve adherence and access. His study found 25% better adherence when patients fill within an integrated network. Onsite specialty pharmacy staff can assist with prior authorizations and injections during visits. Equitable access to integrated specialty pharmacies provides oversight improving outcomes and potentially lowering total costs.

Gottlieb agrees that an onsite specialty pharmacy facilitates a team approach for efficient prior authorization and improving the patient experience. Although her hospital assists patients if they must use an outside specialty pharmacy, they have an onsite team to maximize each patient visit.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.